Although there are promising studies with drugs targeting immune checkpoint receptors (TACTI-002 Part C: A phase II study of eftilagimod alpha, a soluble lymphocyte-activation gene 3 (LAG-3) protein and pembrolizumab), or immunomodulators (BCA101, bifunctional epidermal growth factor receptor (EGFR)/TGFβ inhibitor and pembrolizumab), these are preliminary studies with a small sample size and a tumor response of less than one in two patients [18, 19]. The gene discussed is LAG3; the disease is neoplasm.